Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer

Circulating Tumor Cells Clinical Trial

Official title:

Prospective Validation of Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) as Prognostic Biomarkers in Clear Cell Renal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02499458
• Other study ID #: 105484
• Status: Completed
• Start date: November 2014
• Est. completion date: December 2018

Study information

• Verified date: December 2019
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance. The goal of this proposal is to demonstrate that CTCs can be accurately enumerated and characterized in metastatic clear cell renal cancer (CCRC) and can serve as prognostic/predictive biomarkers to improve treatment. The challenge surrounding CTC analysis in CCRC is that most CTC technologies (including the clinical gold-standard CellSearch®) depend in epithelial markers such as EpCAM that are expressed at low or heterogeneous levels in CCRC. Members of the research team have developed a novel CTC microfluidic technology that can effectively detect CTCs that are completely undetectable by CellSearch® because of very low EpCAM expression, as well as allowing for CTC recovery for downstream molecular characterization. The goal of this proposal is therefore to test the hypotheses that (1) The microfluidics CTC technology will have better sensitivity/specificity relative to the CellSearch in metastatic CCRC; and (2) Enumeration of CTCs in metastatic CCRC patients (n=66) will have prognostic value, while molecular characterization of CTCs for expression of biomarkers (VHL, VEGF, mTOR, HIF1/HIF2, AKT) related to CCRC etiology will be predictive of response/resistance to targeted therapies. Although CCRC is relatively uncommon, the lack of established adjuvant treatments and high cost of targeted therapies in the palliative setting makes the search for new prognostic/predictive biomarkers an important clinical goal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. ECOG performance status 0-2

2. Age over 18 years

3. Diagnosed renal cancer with clear cell histology

4. Metastatic disease

5. Predicted life expectancy over 2 months

6. Targeted treatment with an anti-VEGF or anti-mTOR agent as first or second line therapy

7. Standard imaging evaluation 4 weeks prior to inclusion

8. Planned for standard imaging within 16 weeks after start of therapy

Exclusion Criteria:

1. Presence of substantial comorbidities (uncontrolled heart or respiratory dysfunction, severe renal or hepatic impairment [Cl Cr below 30ml/h OR Bb>3X ULN])

2. History of a malignancy other than non-melanoma skin cancer in the previous 5 years

3. Any other contraindication to targeted treatments.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Circulating Endothelial Cells
• Circulating Tumor Cells
• Clear Cell Renal Cancer
• Kidney Neoplasms
• Neoplastic Cells, Circulating
• Predictive Biomarkers
• Prognostic Biomarkers

Intervention

Other:
• None- observational study

Locations

Country	Name	City	State
Canada	London Health Sciences Centre	London	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Lawson Health Research Institute	Hamilton Health Sciences Corporation, London Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity/specificity of CTC enumeration (microfluidics vs CellSearch)	For comparison of the 2 CTC platforms, a Bland-Altman plot will be constructed. This plot is superior to standard correlation statistics in that it assesses agreement rather than association. Initially we will use a Chi-Square test to compare the 2 methods at a cutoff point of =5 versus <5 CTCs/7.5mL, with simple comparison of PFS at this level. As the cut-off point may not be the same for each method, we will also compare the methods using simple 2X2 contingency tables.	24 months
Primary	Progression free survival (PFS).	Survival analysis will be performed by Kaplan Meier and significance analysis will use the log-rank test. Cox multivariate analysis will be performed to look at the number and molecular characteristics of CTCs as independent prognostic parameters of survival.	24 months
Secondary	Overall survival (OS)	Survival analysis will be performed by Kaplan Meier and significance analysis will use the log-rank test. Cox multivariate analysis will be performed to look at the number and molecular characteristics of CTCs as independent prognostic parameters of survival.	24 months
Secondary	Radiological response	Radiological assessment of disease status will be carried out as standard-of-care and subjected to correlative analysis relative to CTC status, PFS and OS.	within 16 weeks after start of study
Secondary	Molecular characterization of CTCs	CTCs will be recovered from the microfluidics device and subjected to molecular characterization for expression of markers related to angiogenesis and hypoxia.	baseline, 4-6 weeks after start of therapy, 10-12 weeks after start of therapy, post-progression (up to 24 months)
Secondary	Enumeration of CECs	CTCs will be enumerated on both the CellSearch and the novel microfluidic device.	baseline, 4-6 weeks after start of therapy, 10-12 weeks after start of therapy, post-progression (up to 24 months)